

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>5AM Ventures IV, L.P.</u>  (Last) (First) (Middle) 501 2ND STREET, SUITE 350  (Street) SAN FRANCISCO, CA 94107  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Crinetics Pharmaceuticals, Inc. [ CRNX ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) <b>Former 10% holder</b>
	3. Date of Earliest Transaction (Month/Day/Year) 06/21/2019	
		6. Individual or Joint/Group Filing (Check Applicable Line)  <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/21/2019		S		240,000	D	\$22.2	2,267,797	I	See footnote <sup>(1)</sup>
Common Stock	06/21/2019		S		10,000	D	\$22.2	94,489	I	See footnote <sup>(2)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person\*  
5AM Ventures IV, L.P.  
 (Last) (First) (Middle)  
 501 2ND STREET, SUITE 350  
 (Street)  
 SAN FRANCISCO, CA 94107  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
5AM Co-Investors IV, L.P.  
 (Last) (First) (Middle)  
 501 2ND STREET, SUITE 350  
 (Street)  
 SAN FRANCISCO, CA 94107  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
5AM Partners IV, LLC

(Last) (First) (Middle)  
 501 2ND STREET, SUITE 350

---

(Street)  
 SAN FRANCISCO, CA 94107

---

(City) (State) (Zip)

1. Name and Address of Reporting Person\*  
ROCKLAGE SCOTT M

---

(Last) (First) (Middle)  
 501 2ND STREET, SUITE 350

---

(Street)  
 SAN FRANCISCO, CA 94107

---

(City) (State) (Zip)

1. Name and Address of Reporting Person\*  
DIEKMAN JOHN D

---

(Last) (First) (Middle)  
 501 2ND STREET, SUITE 350

---

(Street)  
 SAN FRANCISCO, CA 94107

---

(City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Schwab Andrew J.

---

(Last) (First) (Middle)  
 501 2ND STREET, SUITE 350

---

(Street)  
 SAN FRANCISCO, CA 94107

---

(City) (State) (Zip)

**Explanation of Responses:**

- These securities are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.
- These securities are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Co-Investors IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

5AM VENTURES IV, L.P. By:  
5AM Partners IV, LLC, its  
General Partner /s/ Scott M. 06/25/2019  
Rocklage Managing Member  
5AM CO-INVESTORS IV,  
L.P. By: 5AM Partners IV,  
LLC, its General Partner /s/ 06/25/2019  
Scott M. Rocklage Managing  
Member  
5AM PARTNERS IV, LLC /s/  
Scott M. Rocklage Managing 06/25/2019  
Member  
/s/ Scott M. Rocklage 06/25/2019  
/s/ John D. Diekman 06/25/2019  
/s/ Andrew J. Schwab 06/25/2019

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.  
 \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).  
 \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).  
 Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

